Ixazomib combined with thalidomide and dexamethasone is effective in the treatment of MM, with good short-term efficacy, survival and safety. However, its long-term efficacy needs further observation.

15 days ago

Retrospective data • Journal

B2M (Beta-2-microglobulin)

Ninlaro (ixazomib) • dexamethasone • thalidomide

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma (clinicaltrials.gov)

P1, N=34, Recruiting, University of Pennsylvania | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025

1 month ago

Trial completion date • Trial primary completion date • Combination therapy

lenalidomide • Ninlaro (ixazomib) • dexamethasone • tasquinimod (ABR-215050)

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara (clinicaltrials.gov)

P2, N=401, Active, not recruiting, Stichting European Myeloma Network | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: May 2024 --> Jun 2025

1 month ago

Trial completion date • Trial primary completion date

IGH (Immunoglobulin Heavy Locus)

bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (clinicaltrials.gov)

P2, N=236, Active, not recruiting, Washington University School of Medicine | Trial completion date: Aug 2024 --> Aug 2025

1 month ago

Trial completion date

lenalidomide • Ninlaro (ixazomib)

2ms

A Study of NINLARO® in Chinese Adults With Multiple Myeloma (clinicaltrials.gov)

P=N/A, N=160, Recruiting, Takeda | N=320 --> 160 | Trial completion date: Oct 2025 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Jun 2027

2 months ago

Enrollment change • Trial completion date • Trial primary completion date • Real-world evidence • Real-world

bortezomib • Ninlaro (ixazomib) • carfilzomib

2ms

STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)

P1/2, N=300, Recruiting, Karyopharm Therapeutics Inc | Active, not recruiting --> Recruiting

2 months ago

Enrollment open • Combination therapy

lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)

2ms

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)

P1/2, N=33, Completed, Mayo Clinic | Active, not recruiting --> Completed

2 months ago

Trial completion • Combination therapy

GDF15 (Growth differentiation factor 15)

Ninlaro (ixazomib) • idasanutlin (RG7388)

2ms

MC1382: Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis (clinicaltrials.gov)

P1/2, N=87, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2024 --> May 2025

2 months ago

Trial completion date • Combination therapy

cyclophosphamide • Ninlaro (ixazomib)

2ms

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma (clinicaltrials.gov)

P1/2, N=30, Active, not recruiting, Joseph Tuscano | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

2 months ago

Trial completion date • Trial primary completion date • Combination therapy

Ninlaro (ixazomib) • pomalidomide

3ms

IPoD-790: Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (clinicaltrials.gov)

P2, N=60, Active, not recruiting, Tel-Aviv Sourasky Medical Center | Trial completion date: Oct 2024 --> Sep 2029 | Trial primary completion date: Sep 2024 --> Mar 2026

3 months ago

Trial completion date • Trial primary completion date

lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • pomalidomide

3ms

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant (clinicaltrials.gov)

P2, N=42, Active, not recruiting, University of Chicago | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

3 months ago

Trial completion date • Trial primary completion date • Post-transplantation

lenalidomide • Ninlaro (ixazomib) • dexamethasone

3ms

P2, N=60, Active, not recruiting, Tel-Aviv Sourasky Medical Center | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • pomalidomide

3ms

Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties. (PubMed, Sci Rep)

Here, we used an integrated drug repositioning approach based on transcriptomics data and structure-based virtual screening to identify compounds with gene signatures similar to three known proteasome inhibitors (PIs; bortezomib, MG-132, and MLN-2238)...Using this approach, we identified six compounds with PI properties ((-)-kinetin-riboside, manumycin-A, puromycin dihydrochloride, resistomycin, tegaserod maleate, and thapsigargin)...As shown with bortezomib, only manumycin-A, puromycin dihydrochloride, and tegaserod maleate resulted in excessive accumulation of ubiquitinated proteins and elevated HMOX1 expression. Taken together, our integrated drug repositioning approach and subsequent in vitro validation studies identified six compounds demonstrating properties similar to proteasome inhibitors.

3 months ago

Journal

HMOX1 (Heme Oxygenase 1)

bortezomib • Ninlaro (ixazomib) • MG132

3ms

Association of KRAS Mutation and Gene Pathways in Colorectal Carcinoma: A Transcriptome- and Methylome-Wide Study and Potential Implications for Therapy. (PubMed, Int J Mol Sci)

Our findings suggest the possibility of a better response to anti-CDKN2A therapy with Villosol in KRAS-mutant CRC. Also, the more marked up-regulation of genes in the proteasome pathway in CRC tissue, especially with the KRAS mutation and MSI, may suggest a potential role of a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) in selected CRC patients if necessary.

3 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)

5-fluorouracil • bortezomib • Ninlaro (ixazomib) • carfilzomib

3ms

Ixazomib Rollover Study (clinicaltrials.gov)

P2, N=31, Completed, Takeda | Active, not recruiting --> Completed | Trial completion date: Feb 2027 --> Jul 2024 | Trial primary completion date: Feb 2027 --> Jul 2024

3 months ago

Trial completion • Trial completion date • Trial primary completion date

Ninlaro (ixazomib)

4ms

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients (clinicaltrials.gov)

P4, N=211, Completed, Peking Union Medical College Hospital | Recruiting --> Completed | Trial completion date: Oct 2022 --> Jun 2024 | Trial primary completion date: Oct 2022 --> Jun 2024

4 months ago

Trial completion • Trial completion date • Trial primary completion date • Combination therapy

lenalidomide • Ninlaro (ixazomib)

4ms

A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) (clinicaltrials.gov)

P=N/A, N=191, Completed, Takeda | Recruiting --> Completed | Trial completion date: Jun 2024 --> Aug 2023

4 months ago

Trial completion • Trial completion date • Real-world evidence • Real-world

Ninlaro (ixazomib)

4ms

TOURMALINE-MM3: A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant (clinicaltrials.gov)

P3, N=656, Completed, Takeda | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Sep 2023

4 months ago

Trial completion • Trial completion date

Ninlaro (ixazomib)

4ms

Multicenter, prospective, open-label clinical study of ICD (Ixazomib / cyclophosphamide / dexamethasone) regimen for newly diagnosed POEMS syndrome (ChiCTR2000030072)

P=N/A, N=20, Completed, Shanghai Changzheng Hospital; Shanghai Changzheng Hospital | Recruiting --> Completed

4 months ago

Trial completion

VEGFA (Vascular endothelial growth factor A)

cyclophosphamide • Ninlaro (ixazomib)

4ms

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (clinicaltrials.gov)

P1, N=72, Recruiting, Queen Mary University of London | Phase classification: P1b --> P1 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024

4 months ago

Phase classification • Trial completion date • Trial primary completion date

NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • NEFH (Neurofilament Heavy) • GFAP (Glial Fibrillary Acidic Protein) • NEFL (Neurofilament Light Chain) • S100B (S100 Calcium Binding Protein B)

Ninlaro (ixazomib)

4ms

INFINITE: A Study of Ninlaro in Real World Clinical Practice in China (clinicaltrials.gov)

P=N/A, N=482, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=3000 --> 482

4 months ago

Enrollment closed • Enrollment change • Real-world evidence • Real-world

Ninlaro (ixazomib)

5ms

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)

P1, N=24, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

5 months ago

Trial completion date • Trial primary completion date • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • SDC1 (Syndecan 1) • BAX (BCL2-associated X protein)

Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)

5ms

DeRIVE: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)

P2, N=49, Active, not recruiting, Emory University | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025

5 months ago

Trial completion date • Trial primary completion date

bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone injection

5ms

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)

P2, N=80, Completed, Mayo Clinic | Active, not recruiting --> Completed

5 months ago

Trial completion

lenalidomide • Ninlaro (ixazomib) • Darzalex (daratumumab)

5ms

Ixazomib Rollover Study (clinicaltrials.gov)

P2, N=31, Active, not recruiting, Takeda | Trial completion date: Dec 2023 --> Feb 2027 | Trial primary completion date: Dec 2023 --> Feb 2027

5 months ago

Trial completion date • Trial primary completion date

Ninlaro (ixazomib)

5ms

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib (clinicaltrials.gov)

P2, N=165, Active, not recruiting, Mayo Clinic | N=108 --> 165

5 months ago

Enrollment change

bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • Hemady (dexamethasone tablets) • dexamethasone injection

5ms

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)

P1, N=24, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Jun 2025

5 months ago

Trial completion date • Trial primary completion date • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • SDC1 (Syndecan 1) • BAX (BCL2-associated X protein)

Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)

6ms

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)

P1/2, N=57, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

6 months ago

Trial completion date • Trial primary completion date • Combination therapy • Surgery • Metastases

gemcitabine • doxorubicin hydrochloride • Ninlaro (ixazomib)

6ms

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2025 --> Jan 2031

6 months ago

Trial completion date

Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)

6ms

Enhanced angiogenesis of human umbilical vein endothelial cells via THP-1-derived M2c-like macrophages and treatment with proteasome inhibitors 'bortezomib and ixazomib'. (PubMed, APMIS)

To elucidate the role of macrophages in lung cancer and angiogenesis processes, we established an in vitro co-culture model of A549 or HUVEC with THP-1 cells that polarized to M2c macrophages with hydrocortisone. Additionally, bortezomib inhibited the VEGFB pathway in HUVEC and NFKB1 in A549 cells. The significant findings obtained as a result of this study will provide information regarding angiogenesis induced by M2 macrophages.

6 months ago

Journal

VEGFB (Vascular Endothelial Growth Factor B)

bortezomib • Ninlaro (ixazomib)

6ms

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study (clinicaltrials.gov)

P1, N=14, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> May 2024 | Trial primary completion date: Feb 2025 --> May 2024

6 months ago

Trial completion • Trial completion date • Trial primary completion date

Ninlaro (ixazomib) • dexamethasone

7ms

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)

P2, N=46, Active, not recruiting, University of California, San Diego | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

7 months ago

Trial completion date • Trial primary completion date

Ninlaro (ixazomib) • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)

7ms

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma. (clinicaltrials.gov)

P=N/A, N=420, Recruiting, RenJi Hospital | Not yet recruiting --> Recruiting

7 months ago

Enrollment open

lenalidomide • Ninlaro (ixazomib)

7ms

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial (clinicaltrials.gov)

P3, N=1, Active, not recruiting, National Cancer Institute (NCI) | N=510 --> 1 | Trial completion date: Mar 2024 --> Apr 2025 | Trial primary completion date: Mar 2024 --> Aug 2023

7 months ago

Enrollment change • Trial completion date • Trial primary completion date

lenalidomide • Ninlaro (ixazomib)

8ms

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM (clinicaltrials.gov)

P2, N=18, Recruiting, Larysa Sanchez | N=38 --> 18 | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Feb 2024 --> Dec 2024

8 months ago

Enrollment change • Trial completion date • Trial primary completion date • Combination therapy

lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)

8ms

NCI-2018-02830: Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)

P2, N=40, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 40

8 months ago

Enrollment closed • Enrollment change

bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone injection

8ms

STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)

P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Phase classification: P1b/2 --> P1/2 | N=518 --> 300 | Trial completion date: Jan 2025 --> Apr 2027 | Trial primary completion date: Jan 2025 --> Apr 2027

8 months ago

Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy

8ms

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)

P1/2, N=32, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

8 months ago

Trial completion

Ninlaro (ixazomib) • pomalidomide

8ms

Ixazomib + Pomalidomide + Dexamethasone In MM (clinicaltrials.gov)

P1/2, N=61, Recruiting, Omar Nadeem, MD | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024

8 months ago

Trial completion date • Trial primary completion date

Ninlaro (ixazomib) • pomalidomide

8ms

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)

P1, N=7, Completed, Mayo Clinic | Active, not recruiting --> Completed

8 months ago

Trial completion • Combination therapy

BCL2 (B-cell CLL/lymphoma 2)

Chr t(11;14)

Venclexta (venetoclax) • Ninlaro (ixazomib)

9ms

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study (clinicaltrials.gov)

P1, N=14, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

9 months ago

Trial completion date • Trial primary completion date

Ninlaro (ixazomib) • dexamethasone

9ms

ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. (PubMed, Blood)

Serial analysis of ctDNA mutations in 94 cases revealed that TP53 and KRAS mutations frequently emerge after therapy. Thus, we clarify the genetic characteristics and clonal architecture of ctDNA mutations and demonstrate their superiority over BMPC mutations for prognostic prediction in RRMM.

9 months ago

Journal • Circulating tumor DNA

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog)

TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • ATM mutation • TP53 mutation + KRAS mutation

lenalidomide • Ninlaro (ixazomib) • dexamethasone